<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02236936</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_HNO_PN</org_study_id>
    <nct_id>NCT02236936</nct_id>
  </id_info>
  <brief_title>Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck</brief_title>
  <acronym>AGMT_HNO_PN</acronym>
  <official_title>Randomized Phase III Study: Supplemental Parenteral Nutrition for Patients With Locally Advanced Inoperable Tumors of the Head and Neck, Receiving Definitive Radiotherapy With Cetuximab or Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevention of critical weight loss. In patients with Squamous Cell Carcinoma of the Head and
      Neck (SCCHN) weight loss is a relevant clinical problem during radiotherapy and might result
      in higher treatment related toxicity and discontinuation of a potential curative treatment.
      Thus the investigators want to evaluate the efficacy of overnight parenteral nutritional (PN)
      support in patients with SCCHN treated with curative radiotherapy (RTX) in combination with
      Cetuximab (E) or Cisplatin (P).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that about 60% of patients receiving RTX without supplemental
      PN will suffer from critical weight loss of more than 5% during treatment - supplemental
      overnight PN might result in significant improvement of the nutritional status .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loss of body weight by more than 5% at the end of radiotherapy</measure>
    <time_frame>Difference between baseline and week 8 (after end of RTX)</time_frame>
    <description>Weekly body weight assessments - standardized method for all study sites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioelectrical Impedance Analysis (BIA): reduction of phase angle by &gt; 10% during treatment/observation</measure>
    <time_frame>Prior to and 1 year after start of RTX, within 7 days and 3 months after end of RTX</time_frame>
    <description>Determination of parameters on functional nutritional status: fat-free mass (FFM), total body water (TBW), body fat and phase angle will be evaluated by BIA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>Prior to RTX, 1 week and 3 months after end of RTX and one year after RTX start</time_frame>
    <description>Assessment by the Short Form 12 Health Survey Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Cachexia associated serum lipid parameters</measure>
    <time_frame>Prior to RTX, 1 week and 3 months after end of RTX and one year after RTX start</time_frame>
    <description>Triglycerides, cholesterol, VLDL/LDL/HDL profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokines</measure>
    <time_frame>Prior to RTX, 1 week and 3 months after end of RTX and one year after RTX start</time_frame>
    <description>Cytokines (optional, only for patients who signed additional informed consent form; TNF-a, IL-6, ZAG = Zinc-α2-glycoprotein)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adipose triglyceride lipase activity in adipose tissue</measure>
    <time_frame>Prior to RTX and 3 months after end of RTX</time_frame>
    <description>Incidence of catabolism in cancer patients: Levels of triacylglycerides, glycerol, free fatty acids - obtained optionally by subcutaneous adipose tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of physical strength</measure>
    <time_frame>Prior to RTX, weekly during RTX, within 1 week and 3 months after end of RTX and one year after RTX start</time_frame>
    <description>Handgrip strength measurement, mean value of three consecutive measurements</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of implanted PEG tubes</measure>
    <time_frame>From start of RTX until 1 year after start of RTX</time_frame>
    <description>The number of implanted PEG tubes will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in ability to swallow</measure>
    <time_frame>Prior to RTX, one week after RTX, one year after start of RTX</time_frame>
    <description>Ability to swallow will be assessed using the Sydney Swallow Questionnaire (SSQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>General food intake</measure>
    <time_frame>Prior to RTX, during 7 week RTX, one week after RTX</time_frame>
    <description>General food intake will be estimated by a weekly adapted nutritionDay questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute toxicity during radiotherapy</measure>
    <time_frame>During 7 weeks of radiotherapy, at end of radiotherapy and 3 months after radiotherapy</time_frame>
    <description>Acute toxicity according to Common Terminology Criteria for Adverse Events (CTCAE 4.0.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronic toxicity after treatment</measure>
    <time_frame>One year after treatment start</time_frame>
    <description>Chronic toxicity evaluated according to RTOG (Radiation Therapy Oncology Group)/EORTC (European Organisation for Research and Treatment of Cancer) - Toxicity Criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose and dose intensity of radiotherapy</measure>
    <time_frame>At start and end of radiotherapy (duration of radiotherapy 7 weeks)</time_frame>
    <description>Dose and dose intensity including delay of scheduled therapy and absolute dose of radiotherapy applied.</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression-free (PFS)</measure>
    <time_frame>From start until one year after start of RTX</time_frame>
    <description>The study will be finished one year post RTX and clinical al data on PFS will be obtained. In addition, patient will be asked to agree to collection of information regarding PFS even after completion of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start until one year after start of RTX</time_frame>
    <description>The study will be finished one year post RTX and clinical data on OS will be obtained. In addition, patient will be asked to agree to collection of information regarding OS even after completion of the trial.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Squamous Cell Carcinoma of the Hypopharynx Stage III</condition>
  <condition>Squamous Cell Carcinoma of the Hypopharynx Stage IV</condition>
  <condition>Laryngeal Squamous Cell Carcinoma Stage III</condition>
  <condition>Laryngeal Squamous Cell Carcinoma Stage IV</condition>
  <condition>Oropharyngeal Squamous Cell Carcinoma Stage III</condition>
  <condition>Oropharyngeal Squamous Cell Carcinoma Stage IV</condition>
  <condition>Squamous Cell Carcinoma of the Oral Cavity Stage III</condition>
  <condition>Squamous Cell Carcinoma of the Oral Cavity Stage IV</condition>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm A - Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.
Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Parenteral over night nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss &gt;5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.
Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard care of parenteral nutrition</intervention_name>
    <description>Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed</description>
    <arm_group_label>Arm A - Standard of care</arm_group_label>
    <other_name>PN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parenteral over night nutrition</intervention_name>
    <description>Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.</description>
    <arm_group_label>Arm B - Parenteral over night nutrition</arm_group_label>
    <other_name>Emulsion for infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Weekly during radiotherapy; not given if cisplatin is given during radiotherapy
Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)</description>
    <arm_group_label>Arm A - Standard of care</arm_group_label>
    <arm_group_label>Arm B - Parenteral over night nutrition</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin total dose of &gt;200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab</description>
    <arm_group_label>Arm A - Standard of care</arm_group_label>
    <arm_group_label>Arm B - Parenteral over night nutrition</arm_group_label>
    <other_name>Cisplatinum</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>70 Gy / 5 fractions per week, over 7 weeks</description>
    <arm_group_label>Arm A - Standard of care</arm_group_label>
    <arm_group_label>Arm B - Parenteral over night nutrition</arm_group_label>
    <other_name>RTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient who is eligible for definitive curative radio-chemotherapy with Cisplatin
             or radio-immunotherapy with Cetuximab.

          -  Written informed consent obtained prior to any study specific screening activities and
             patients have to be able to comply with this protocol.

          -  Histologically confirmed local advanced squamous cell carcinoma of the Larynx,
             Hypopharynx, Oropharynx or Cavum oris treated with definitive radiotherapy in
             combination with Cisplatin or Cetuximab.

          -  p16 status available

          -  Age ≥ 18

          -  Women of childbearing potential must have a negative pregnancy test at screening and
             must use effective contraception.

        Exclusion Criteria:

          -  Distant metastases

          -  Prior radiation (Head and neck area)

          -  Pregnant or lactating women

          -  History of other malignancy; yet patients who have been disease-free for 5 years or
             patients with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible.

          -  Concurrent other cancer therapy (chemotherapy, immunotherapy, antihormonal or biologic
             therapy) or concurrent treatment with an investigational drug.

          -  Serious medical or psychiatric disorders that would interfere with the patient's
             safety or informed consent.

          -  Participation in another interventional clinical study at time of study inclusion
             (except follow-up period without treatment for more than 30 days) or denial of the
             simultaneous participation in a non-interventional study by the PI of the study
             center.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Keil, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanuschkrankenhaus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander De Vries, Univ.Doz. MD</last_name>
      <phone>+43 5522303</phone>
      <phone_ext>3300</phone_ext>
      <email>alexander.devries@lkhf.at</email>
    </contact>
    <investigator>
      <last_name>Alexander De Vries, Univ.Doz. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz, HNO Universitätsklinik</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietmar Thurnher, Prof.,MD</last_name>
      <phone>+43 316 3851</phone>
      <phone_ext>3448</phone_ext>
      <email>dietmar.thurnher@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Reinisch, MD, Senior</last_name>
      <phone>+43 316 3851</phone>
      <phone_ext>3448</phone_ext>
      <email>sabine.reinisch@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Dietmar Thurnher, Prof.,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee, HNO-Abteilung</name>
      <address>
        <city>Klagenfurt am Wörthersee</city>
        <zip>A-9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Primosch, MD</last_name>
      <phone>+43 463 538</phone>
      <phone_ext>27107</phone_ext>
      <email>thomasprimosch@gmx.at</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Primosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz - Barmherzigen Schwestern, Abteilung f. HNO, Kopf- und Halschirurgie</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magdalena Sturm, DI</last_name>
      <phone>+43 7327677</phone>
      <phone_ext>7521</phone_ext>
      <email>magdalena.sturm@ordensklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Martin Burian, Prof.Dr.</last_name>
      <phone>+43 7327677</phone>
      <phone_ext>4828</phone_ext>
      <email>martin.burian@ordenskliniku.at</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Burian, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanuschkrankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanna Müller, MSc</last_name>
      <phone>+43 1 91021</phone>
      <phone_ext>85435</phone_ext>
      <email>hanna.mueller@wgkk.at</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Holzer, Mag.</last_name>
      <phone>+43 1 91021</phone>
      <phone_ext>85435</phone_ext>
      <email>kathrin.holzer@wgkk.at</email>
    </contact_backup>
    <investigator>
      <last_name>Felix Keil, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.agmt.at</url>
    <description>Sponsor</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Head and neck</keyword>
  <keyword>SCCHN</keyword>
  <keyword>Parenteral nutrition</keyword>
  <keyword>Larynx</keyword>
  <keyword>Hypopharynx</keyword>
  <keyword>Cavum oris</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

